Current insulin analogues in the treatment of diabetes: emphasis on type 2 diabetes

Bibliography

• Diabetes Data and Trends. Atlanta, GA: Centers for Disease Control and Prevention. 2009. Available from: http://www.cdc.gov/diabetes/statistics/complications_national.htm [Last accessed 14 December 2011]
   Google Scholar
• Annual number (in thousands) of new cases of diagnosed diabetes among adults aged 18 – 79 years, United States, 1980 – 2009. Diabetes Data and Trends. Atlanta, GA: Centers for Disease Control and Prevention. 2009. Available from: http://www.cdc.gov/diabetes/statistics/incidence/fig1.htm [Last accessed 14 December 2011]
   Google Scholar
• Ray JA, Valentine WJ, Secnik K, Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Curr Med Res Opin 2005;12:1617-29
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes—2010. Diabetes Care 2010;33(Suppl 1):S11-61
   PubMed Web of Science ®Google Scholar
• Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care 2008;31:81-6
   PubMed Web of Science ®Google Scholar
• Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-42
   PubMed Web of Science ®Google Scholar
• Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults with diagnosed type 2 diabetes. Diabetes Care 2004;27:17-20
   PubMed Web of Science ®Google Scholar
• Ismail-Beigi F, Moghissi E, Tiktin M, Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 2011;154:554-49
   PubMed Web of Science ®Google Scholar
• Nathan DM. Finding new treatments for diabetes – how many, how fast... how good? N Engl J Med 2007;356:437-40
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005. Department of Health and Human Services, Centers for Disease Control and Prevention; Atlanta: 2005
   Google Scholar
• The AMD Annals 2009 Working Group. Longitudinal analysis of quality indicators of diabetes care in Italy (2004 – 2007). Associazione Medici Diabetologi, Rome; 2009. Available from: http://www.infodiabetes.it/files/2009_annali_AMD_eng.pdf
   Google Scholar
• Peyrot M, Rubin RR, Lauritzen T, Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673-9
   PubMed Web of Science ®Google Scholar
• Karter AJ, Subramanian U, Saha C, Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care 2010;33:733-5
   PubMed Web of Science ®Google Scholar
• Giugliano D, Esposito K. Clinical inertia as a clinical safeguard. JAMA 2011;305:1591-2
   PubMed Web of Science ®Google Scholar
• Giugliano D, Esposito K. Clinical inertia and uncertainty in medicine. JAMA 2011;206:383-4
   Google Scholar
• Hirsch IB. Insulin analogues. N Engl J Med 2005;352:174-83
   PubMed Web of Science ®Google Scholar
• Crasto W, Jarvis J, Khunti K, Davies MJ. New insulins and new insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. Postgrad Med J 2009;85:257-67
   Google Scholar
• Evans M, Schumm-Draeger PM, Vora J, King AB. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes Obes Metab 2011;13:677-84
   PubMed Web of Science ®Google Scholar
• Plank J, Wutte A, Brunner G, A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 2002;25:2053-7
   PubMed Web of Science ®Google Scholar
• Gray M, Boland EA, Tamborlane WV. Use of lispro insulin and quality of life in adolescents on intensive therapy. Diabetes Educ 1999;25:934-41
   PubMed Web of Science ®Google Scholar
• Plank J, Siebenhofer A, Berghold A, Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005;165:1337-44
   PubMed Web of Science ®Google Scholar
• Hompesch M, Ocheltree SM, Wondmagegnehu ET, Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. Curr Med Res Opin 2009;25:2679-87
   PubMed Web of Science ®Google Scholar
• Smith U, Gale EAM. Does diabetes therapy influence the risk of cancer? Diabetologia 2009;52:1441-5
   Google Scholar
• Vigneri R, Squatrito S, Sciacca L. Insulin and its analogs: actions via insulin and IGF receptors. Acta Diabetol 2010;47:271-8
   PubMed Web of Science ®Google Scholar
• Gough SCL, Belda-Iniesta C, Poole C, Insulin Therapy in diabetes and cancer risk: current understanding and implications for future study. Proceedings from a meeting of a European Insulin Safety Consensus Panel, convened and sponsored by Novo Nordisk, held Tuesday October 5, 2010 at The Radisson Edwardian Heathrow Hotel, Hayes, Middlesex, UK. Adv Ther 2011;28(Suppl 5):1-18
   PubMedGoogle Scholar
• Werner H, Weinstein D, Yehezkel E, Laron Z. Controversies in the use of insulin analogues. Expert Opin Biol Ther 2011;11:199-209
   PubMed Web of Science ®Google Scholar
• Guidance for industry: diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. Food and Drug Administration, Center for Drug Evaluation and Research (CDER); Rcockville, MD: 2008
   Google Scholar
• Hauber A, Gale EAM. The market in diabetes. Diabetologia 2006;49:247-52
   PubMed Web of Science ®Google Scholar
• The Dream Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006;368:1096-105
   PubMed Web of Science ®Google Scholar
• Bolli GB, Di Marchi RD, Park GD, Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999;42:1151-67
   PubMed Web of Science ®Google Scholar
• Plank J, Siebenhofer A, Berghold A, Systemic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005;165:1337-44
   PubMed Web of Science ®Google Scholar
• Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6
   PubMed Web of Science ®Google Scholar
• Home PD, Fritsche A, Schinzel S, Massi-Benedetti M. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes Obes Metab 2010;12:772-9
   PubMed Web of Science ®Google Scholar
• Lucidi P, Porcellati F, Rossetti P, Pharmacokinetics and pharmacodynamics of therapeutic dose of basal insulins NPH, glargine and detemir after one week of daily administration at bedtime in type 2 diabetes: a randomized, cross-over study. Diabetes Care 2011;34:1312-14
   PubMed Web of Science ®Google Scholar
• Porcellati F, Lucidi P, Rossetti P, Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus. Diabetes Care 2011;34:2521-3
   PubMed Web of Science ®Google Scholar
• Swinnen SG, Simon AC, Holleman F, Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011(7):CD006383
   PubMed Web of Science ®Google Scholar
• Fogelfeld L, Dharmalingam M, Robling K, SA, Randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with type 2 diabetes. Diabet Med 2010;27:181-8
   PubMed Web of Science ®Google Scholar
• Esposito K, Ciotola M, Maiorino MI, Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. Ann Intern Med 2008;149:531-9
   PubMed Web of Science ®Google Scholar
• Strojek K, Shi C, Carey MA, Jacober SJ. Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens: a randomized trial. Diabetes Obes Metab 2010;12:916-22
   PubMed Web of Science ®Google Scholar
• Koivisto V, Cleall S, Pontiroli AE, Giugliano D. Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial. Diab Obes Metab 2011;13:1149-57
   PubMed Web of Science ®Google Scholar
• Holman RR, Farmer AJ, Davies MJ, Three-year efficacy of complex regimens in type 2 diabetes. N Engl J Med 2009;361:1736-47
   PubMed Web of Science ®Google Scholar
• Bonora E, Corrao G, Bagnardi V, Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetologia 2006;49:846-54
   PubMed Web of Science ®Google Scholar
• Giugliano D, Maiorino MI, Bellastella G, Efficacy of insulin analogs in achieving the hemoglobin A1c target of < 7% in type 2 diabetes meta-analysis of randomized controlled trials. Diabetes Care 2011;34:510-17
   PubMed Web of Science ®Google Scholar
• Pontiroli AE, Miele L, Morabito A. Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes. Systematic review and meta-analysis. Diab Obes Metab 2011;13:1008-19
   PubMed Web of Science ®Google Scholar
• Bolli GB, Lucidi P, Porcellati F, Fanelli CG. Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in type 2 diabetes. Diabetes Care 2011;34(Suppl 2):S220-S2244
   PubMedGoogle Scholar
• Lebovitz HE. Insulin: potential negative consequences of early routine use in patients with type 2 diabetes. Diabetes Care 2011;34(Suppl 2):S225-30
   PubMed Web of Science ®Google Scholar
• Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
   PubMed Web of Science ®Google Scholar
• ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T, Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39
   PubMed Web of Science ®Google Scholar
• Rhoads GG, Kosiborod M, Nesto RW, Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine. Am J Cardiol 2009;104:910-16
   PubMed Web of Science ®Google Scholar
• Raz I, Wilson PW, Strojek K, Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009;32:381-6
   PubMed Web of Science ®Google Scholar
• Raz I, Ceriello A, Wilson PW, Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia. Diabetes Care 2011;34:1511-13
   PubMed Web of Science ®Google Scholar
• Jonassen I, Havelund S, Ribel U, Insulin degludec is a new generation ultra-long acting basal insulin with a unique mechanism of protraction based on multi-hexamer formation. Diabetes 2010;59(Suppl 1):A11
   Google Scholar
• Zinman B, Fulcher G, Rao PV, Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase II trial. Lancet 2011;377:924-31
   PubMed Web of Science ®Google Scholar
• Heise T, Tack CJ, Cuddihy R, A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care 2011;34:669-74
   PubMed Web of Science ®Google Scholar
• Scholtz HE, Pretorius SG, Wessels DH, Becker RHA. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 2005;48:1988-95
   PubMed Web of Science ®Google Scholar
• Siegelaar SE, Holleman F, Hoekstra JB, DeVries JH. Glucose variability; does it matter? Endocr Rev 2010;31:171-82
   PubMed Web of Science ®Google Scholar
• Drug Prices. Bellvue, WA Drugstore.com,2011. Available from: www.drugstore.com [Last accessed 14 December 2011]
   Google Scholar
• Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab 2007;9:209-17
   PubMed Web of Science ®Google Scholar
• Malone JK, Kerr LF, Campaigne BN, LisproMixture- Glargine Study Group. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004;26:2034-44
   PubMed Web of Science ®Google Scholar
• Malone JK, Bai S, Campaigne BN, Twice-daily premixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. Diabet Med 2005;22:374-81
   PubMed Web of Science ®Google Scholar
• Raskin P, Allen E, Hollander P, INITIATE Study Group. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-5
   PubMed Web of Science ®Google Scholar
• Kann PH, Wascher T, Zackova V, Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 2006;114:527-32
   PubMed Web of Science ®Google Scholar
• Jacober SJ, Scism-Bacon JL, Zagar AJ. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naive patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes Obes Metab 2006;8:448-55
   PubMed Web of Science ®Google Scholar
• Kazda C, Hulstrunk H, Helsberg K, Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications 2006;20:145-52
   PubMed Web of Science ®Google Scholar
• Holman RR, Thorne KI, Farmer AJ, 4- T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-30
   PubMed Web of Science ®Google Scholar
• Robbins DC, Beisswenger PJ, Ceriello A, Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and preand postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther 2007;29:2349-64
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Ahmann AJ, Colon G, Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lisproprotamine suspension/lispro) versus basal/ bolus (glargine/lispro) therapy. Diabetes Care 2008;31:20-5
   PubMed Web of Science ®Google Scholar
• Liebl A, Prager R, Binz K, PREFER Study Group. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab 2009;11:45-52
   PubMed Web of Science ®Google Scholar
• Buse JB, Wolffenbuttel BH, Herman WH, DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care 2009;32:1007-13
   PubMed Web of Science ®Google Scholar
• Strojek K, Bebakar WM, Khutsoane DT, Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Curr Med Res Opin 2009;25:2887-94
   PubMed Web of Science ®Google Scholar
• Holman RR, Farmer AJ, Davies MJ, 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009;361:1736-47
   PubMed Web of Science ®Google Scholar